Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents

Background: Hypomethylating agents (HMA) are the only approved agents to treat CMML. Phase III trials for HMA included few patients (pts) with myelodysplastic CMML (MD-CMML) but excluded pts with myeloproliferative CMML (MP-CMML). In pts eligible for Dacota trial (Itzykson et al Blood (2020) 136 (Supplement 1): 53-54), the reported outcomes have been variable in those treated with HMA. Therefore, we sought to define the outcomes of pts with CMML treated with HMA stratified by disease subtype.